Company Summary - IS Pharma PLC (LSE:ISPH)
62.00p
0.00p
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £19.067m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Development and commercial exploitation of healthcare products and related activities
| Financials - Interim (7/12/2009) | ||
|---|---|---|
| Turnover | £m | 5.93 |
| Pre-tax Profit | £m | 0.52 |
| EPS | p | 1.20 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Geoff McMillan | Chairman |
| Tim Wright | Chief Executive |
| Matthew Hall | Finance Director & Company Sec |
Products Brands & Subsidiaries
Products & Brands
Acoranil©; Aloxi; AquiHex; AquiHex© 2%; ContiSol; Cryogesic; Dermogesic; Dermogesic©; Haemopressin; Isoplex; Isoplex©...
Subsidiaries
Acorus Therapeutics Ltd; Speciality European Pharma International AG; IS Pharmaceuticals Ltd
Broker Sentiment (0 brokers)
No current consensus recommendation available.
| Heading | Date |
|---|---|
| Acquisition of the exclusive rights f... | 04/03/2010 |
| Granting of Supply Rights & ... | 11/01/2010 |
| Interim Results | 07/12/2009 |